» Articles » PMID: 27579340

Data on Correlations Between T Cell Subset Frequencies and Length of Partial Remission in Type 1 Diabetes

Overview
Journal Data Brief
Date 2016 Sep 1
PMID 27579340
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Partial remission in patients newly diagnosed with type 1 diabetes is a period of good glucose control that can last from several weeks to over a year. The clinical significance of the remission period is that patients might be more responsive to immunotherapy if treated within this period. This article provides clinical data that indicates the level of glucose control and insulin-secreting β-cell function of each patient in the study at baseline (within 3 months of diagnosis), and at 3, 6, 9, 12, 18 and 24 months post-baseline. The relative frequency of immune cell subsets in the PBMC of each patient and the association between the frequency of immune cell subsets measured and length of remission is also shown. These data support the findings reported in the accompanying publication, "A pilot study showing associations between frequency of CD4+ memory cell subsets at diagnosis and duration of partial remission in type 1 diabetes" (Moya et al., 2016) [1], where a full interpretation, including biological relevance of the study can be found.

Citing Articles

CD4+CD25+CD127hi cell frequency predicts disease progression in type 1 diabetes.

Narsale A, Lam B, Moya R, Lu T, Mandelli A, Gotuzzo I JCI Insight. 2020; 6(2).

PMID: 33301420 PMC: 7934872. DOI: 10.1172/jci.insight.136114.


Cancer-driven changes link T cell frequency to muscle strength in people with cancer: a pilot study.

Narsale A, Moya R, Ma J, Anderson L, Wu D, Garcia J J Cachexia Sarcopenia Muscle. 2019; 10(4):827-843.

PMID: 30977974 PMC: 6711422. DOI: 10.1002/jcsm.12424.


Dataset on significant risk factors for Type 1 Diabetes: A Bangladeshi perspective.

Asaduzzaman S, Masud F, Bhuiyan T, Ahmed K, Paul B, Rahman S Data Brief. 2019; 21:700-708.

PMID: 30666315 PMC: 6205358. DOI: 10.1016/j.dib.2018.10.018.


Human CD4 CD25 CD127 cells and the Th1/Th2 phenotype.

Narsale A, Moya R, Davies J Clin Immunol. 2018; 188:103-112.

PMID: 29330114 PMC: 5826897. DOI: 10.1016/j.clim.2018.01.003.


Memory T Cells in Type 1 Diabetes: the Devil is in the Detail.

Narsale A, Davies J Curr Diab Rep. 2017; 17(8):61.

PMID: 28670660 DOI: 10.1007/s11892-017-0889-9.

References
1.
Muhammad B, Swift P, Raymond N, Botha J . Partial remission phase of diabetes in children younger than age 10 years. Arch Dis Child. 1999; 80(4):367-9. PMC: 1717883. DOI: 10.1136/adc.80.4.367. View

2.
Mortensen H, Hougaard P, Swift P, Hansen L, Holl R, Hoey H . New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care. 2009; 32(8):1384-90. PMC: 2713624. DOI: 10.2337/dc08-1987. View

3.
Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A . Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009; 30(6):899-911. DOI: 10.1016/j.immuni.2009.03.019. View

4.
Moya R, Robertson H, Payne D, Narsale A, Koziol J, Davies J . A pilot study showing associations between frequency of CD4(+) memory cell subsets at diagnosis and duration of partial remission in type 1 diabetes. Clin Immunol. 2016; 166-167:72-80. PMC: 4902740. DOI: 10.1016/j.clim.2016.04.012. View